Total Hip Registry

July 22, 2016 updated by: R. David Heekin, MD, Heekin Orthopedic Research Institute

Objective

Describe the clinical and demographic characteristics of patients who undergo hip arthroplasty and document post operative outcomes.

Examine the relationship between processes of care, hospital and surgeon associated outcomes

Provide expanded data to characterize existing and evolving practice patterns, delivery of care, and resource utilization in the management of knee arthroplasty patients.

Analyze and design ancillary studies to address unanswered questions.

Disseminate findings through publication in peer-reviewed scientific journals.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

942

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Jacksonville, Florida, United States, 32204
        • Heekin Orthopedic Specialists

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 93 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Population: All total hip replacements

Selection: Males and non-pregnant females over the age of 21

Description

Inclusion Criteria:

  • Patient requires total hip Arthroplasty
  • Patient has signed IRB approved informed consent

Exclusion Criteria:

  • Less than 21 years of age
  • Patient is a prisoner

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Total hip
all consented patients receiving total hip arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Harris Hip Score
Time Frame: 2 weeks, 6 weeks, 3 months, 6 months, 1, 2, 5, 10 years
2 weeks, 6 weeks, 3 months, 6 months, 1, 2, 5, 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Heekin Orthopedic Research Institute

Collaborators

DePuy Orthopaedics
ConforMIS, Inc.
Stryker Orthopaedics

Investigators

  • Principal Investigator: Richard D Heekin, MD, Heekin Orthopedic Specialists

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2005

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

May 26, 2010

First Submitted That Met QC Criteria

May 27, 2010

First Posted (Estimate)

May 28, 2010

Study Record Updates

Last Update Posted (Estimate)

July 26, 2016

Last Update Submitted That Met QC Criteria

July 22, 2016

Last Verified

July 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 05-09-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe